Literature DB >> 1234636

World Health Organization classification and nomenclature of ovarian cancer.

R E Scully.   

Abstract

A World Health Organization (WHO) committee of representatives from seven nations published a histologic typing of ovarian tumors in 1973. Their typing of common epithelial tumor was based largely on the classification by the International Federation of Gynaecology and Obstetrics (FIGO), and the single most important concept to emerge from the FIGO and WHO classifications was the distinction among common epithelial tumors between tumors of borderline malignancy and carcinomas. A second general category of ovarian tumors, some of which are clinically malignant, was designated by the WHO committee as sex cord-stromal tumors (neoplasms containing granulosa, theca, collagen-producing stromal, Sertoli, and/or Leydig cells). The WHO classification of germ cell tumors emphasized the necessity of careful examination of the gross specimen with jucicious sampling for microscopic evaluation. The classification and nomenclature used within an institution should be the one most conductive to mutual understanding and optimal patient care; however, when that nomenclature has to be translated into one with more widespread acceptance, the WHO classification, based on the earlier and widely adopted classification of FIGO, is presently the most deserving of universal usage.

Entities:  

Mesh:

Year:  1975        PMID: 1234636

Source DB:  PubMed          Journal:  Natl Cancer Inst Monogr        ISSN: 0083-1921


  16 in total

1.  MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.

Authors:  Chandra Bartholomeusz; Tetsuro Oishi; Hitomi Saso; Ugur Akar; Ping Liu; Kimie Kondo; Anna Kazansky; Savitri Krishnamurthy; Jangsoon Lee; Francisco J Esteva; Junzo Kigawa; Naoto T Ueno
Journal:  Mol Cancer Ther       Date:  2011-12-05       Impact factor: 6.261

2.  INSR gene polymorphisms correlate with sensitivity to platinum-based chemotherapy and prognosis in patients with epithelial ovarian cancer.

Authors:  J-L Hu; X-L Hu; Q Han; A-Y Guo; C-J Wang; Y-Y Wen; S-D Cang
Journal:  Gene Ther       Date:  2017-04-24       Impact factor: 5.250

3.  Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.

Authors:  Hiroaki Itamochi; Misaki Kato; Mayumi Nishimura; Nao Oumi; Tetsuro Oishi; Muneaki Shimada; Shinya Sato; Jun Naniwa; Seiya Sato; Michiko Nonaka; Akiko Kudoh; Naoki Terakawa; Junzo Kigawa; Tasuku Harada
Journal:  Hum Cell       Date:  2013-02-21       Impact factor: 4.174

4.  Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression.

Authors:  Seiya Sato; Hiroaki Itamochi; Nao Oumi; Youhei Chiba; Tetsuro Oishi; Muneaki Shimada; Shinya Sato; Jun Chikumi; Michiko Nonaka; Akiko Kudoh; Hiroaki Komatsu; Tasuku Harada; Toru Sugiyama
Journal:  Hum Cell       Date:  2016-03-09       Impact factor: 4.174

5.  Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary.

Authors:  Hiroaki Itamochi; Nao Oumi; Tetsuro Oishi; Tadahiro Shoji; Hiroyuki Fujiwara; Toru Sugiyama; Mitsuaki Suzuki; Junzo Kigawa; Tasuku Harada
Journal:  Int J Clin Oncol       Date:  2015-03-06       Impact factor: 3.402

6.  BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma--an Indian study.

Authors:  V Shilpa; Rahul Bhagat; C S Premalata; V R Pallavi; G Ramesh; Lakshmi Krishnamoorthy
Journal:  Tumour Biol       Date:  2014-01-03

7.  The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer.

Authors:  Nicole E Campbell; James Greenaway; Jack Henkin; Roger A Moorehead; Jim Petrik
Journal:  Neoplasia       Date:  2010-03       Impact factor: 5.715

8.  CD133 expression associated with poor prognosis in ovarian cancer.

Authors:  Jing Zhang; Xiaoqing Guo; Doo Young Chang; Daniel G Rosen; Imelda Mercado-Uribe; Jinsong Liu
Journal:  Mod Pathol       Date:  2011-11-11       Impact factor: 7.842

9.  Loss of DNA mismatch repair protein hMSH6 in ovarian cancer is histotype-specific.

Authors:  Qihui Jim Zhai; Daniel Gustavo Rosen; Karen Lu; Jinsong Liu
Journal:  Int J Clin Exp Pathol       Date:  2008-01-31

10.  Establishment and characterization of a clear cell carcinoma cell line, designated NOCC, derived from human ovary.

Authors:  Akihiro Ohyama; Junko Toyomura; Toshiaki Tachibana; Seiji Isonishi; Haruka Takahashi; Hiroshi Ishikawa
Journal:  Hum Cell       Date:  2016-08-19       Impact factor: 4.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.